BridgeBio Pharma Inc

BridgeBio Pharma Inc. engages in the discovery development and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265 a small molecule stabilizer of transthyretin or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy or ATTR-CM; BBP-831 a small molecule selective FGFR1-3 inhibitor which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631 an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia or CAH driven by 21-hydroxylase deficiency or 21OHD. The company also develops Encaleret a small molecule antagonist of the calcium sensing receptor or CaSR which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1 or ADH1; and BBP-711 for the treatment of hyperoxaluria as well as patients suffering from recurrent kidney stones. In addition it engages in developing products for Mendelian oncology and gene therapy diseases. BridgeBio Pharma Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research Inc. The company was founded in 2015 and is headquartered in Palo Alto California.